The Delta variant is doing that again infections are increasing exponentially in many countries where the percentage of vaccinated is quite large and even in some territories where the vaccinated population is higher than the unvaccinated. Israel or the United Kingdom, to give two examples, are seeing how new cases have multiplied in recent weeks, even despite having a large part of the population immunized.
In fact, from Israel the Ministry of Health has come to ensure that the effectiveness of Pfizer, a vaccine widely used in the country, against the Delta variant has decreased going from 94.3% to 64% against the Delta variant.
However, Pfizer Chief Scientist Mikael Dolsten, has stepped out of speculation and He has denied that his company’s vaccine is losing efficacy against the Delta variant. In fact, he has assured that the reason why infections have risen in recent weeks in Israel is because the vast majority of the population received the doses between January and February, so that the antibodies generated by the serum would have already been reduced.
In this sense, Dolsten acknowledges that the effectiveness of your vaccine may have suffered wear and tear, since the virus has undergone mutations, but has qualified that Pfizer’s effectiveness in avoiding hospitalizations and the most serious cases caused by the Indian variant does remain above 93%.
Authorization for a third dose
Although the vaccine continues to be highly effective according to Pfizer, from the company they have advanced that they will ask the European Union and United States regulators authorization to market the third dose of your COVID-19 vaccine. According to studies conducted by Pfizer, a third puncture increases antibody levels five to ten times higher against the parent strain of the coronavirus and the Beta variant (South African).
Likewise, against the Delta variant, from Pfizer they assure that there are still no conclusive studies, but they hope that a third booster dose has a similar behavior against the original strain or the Beta.
New vaccine against Delta variant
In any case, the consortium formed by Pfizer and BioNTech has been developing a Specific vaccine against the Delta variant, a serum that is already being manufactured at the BioNTech laboratories in Mainz (Germany). The multinational is confident of starting clinical studies on the effectiveness of this new Delta vaccine this August, provided that regulators authorize human testing of this new version.
–
